전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,403 programs
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

Anti-CTLA-4/PD-1 expressing MUC1-CAR-T (Anti-CTLA-4/PD-1 expressing MUC1-CAR-T)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-Cluster of Differentiation (CD, Anti-Cluster of Differentiation, Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR))

ALL; B Cell Lymphoma · ALL

#ALL#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleBenaroya Research InstitutePhase 2

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

Colorectal Cancer; Cholangiocarcinoma · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#ColorectalCancer+2
Trials 1Status Active
CGTLimited DatastaleOhio State University Comprehen…Phase 1

Anti-GARP Chimeric Antigen Receptor-T Cells (Anti-GARP Chimeric Antigen Receptor-T Cells)

Recurrent Malignant Glioma; Recurrent WHO Grade 3 Glioma · Recurrent Malignant Glioma

#RecurrentMalignantGlioma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-GD2-CAR engineered T cells (Anti-GD2-CAR engineered T cells)

Sarcoma; Osteosarcoma · GD2

#GD2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-GPRC5D CAR-T cells infusion (Anti-GPRC5D CAR-T cells infusion)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · GPRC5D

#GPRC5D#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleZhi YangPhase 2

Anti-HER2 CAR-T (Anti-HER2 CAR-T)

Breast Cancer; Ovarian Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

Anti-LILRA6 CAR-T cells (Anti-LILRA6 CAR-T cells)

Refractory Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

Anti-LeY-CAR-transduced T cells (Anti-LeY-CAR-transduced T cells)

Myeloid Malignancies · Myeloid Malignancies

#MyeloidMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Anti-PD-1 Antibody Plus Chidamide and Rituximab (Anti-PD-1 Antibody Plus Chidamide and Rituximab)

Relapsed or Refractory DLBCL · PD-1

#PD-1#Antibody#Phase2#monoclonal-antibody#RelapsedorRefractoryDLBCL+1
Trials 1Status Active
AntibodyLimited DatastaleGustave Roussy, Cancer Campus, …Phase 2

atezolizumab (Tecentriq, Anti-PD-L1 antibody atezolizumab)

Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#PatientsWithMetastaticTumoursCol+3
Trials 1Status Active
CGTLimited DatastaleJiangsu Topcel-KH Pharmaceutica…Phase 1

Anti-PD1 armored CD19 CAR-T cells (Anti-PD1 armored CD19 CAR-T cells)

Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
ADCLimited DatastaleSun Yat-sen UniversityPhase 3

Anti-PD1 combined with Becotatug Vedotin (Anti-PD1 combined with Becotatug Vedotin)

Nasopharyngeal Cancinoma (NPC) · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#ADC#Phase3#antibody-drug-conjugate#Sun
Trials 1Status Recruiting
CGTLimited DatastalePromiCell Therapeutics, Inc.Phase 2

Anti-STEAP1 CAR T-cells (Anti-STEAP1 CAR T-cells)

Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleJanssenApproved

Infusion (Anti-TNF: Infliximab, Anti-TNF: Infliximab (Infusion))

Crohn's Disease; Inflammatory Bowel Disease · Crohn's Disease

#CrohnsDisease#Antibody#Approved#monoclonal-antibody#InflammatoryBowelDisease+1
Trials 1Status Active
AntibodyLimited DatastaleAbbVieApproved

Subcutaneus (Anti-TNF:Adalimumab, Anti-TNF:Adalimumab (Subcutaneus))

Crohn's Disease; Inflammatory Bowel Disease · Crohn's Disease

#CrohnsDisease#Antibody#Approved#monoclonal-antibody#InflammatoryBowelDisease+1
Trials 1Status Active
CGTLimited DatastaleHenan Cancer HospitalPhase 2

Anti-Trop2 CAR-NK cell (Anti-Trop2 CAR-NK cell)

Non-Small Cell Lung Cancer NSCLC · TROP2

#TROP2#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-Tumor Necrosis Factor (TNF, Anti-Tumor Necrosis Factor, Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, Large-Cell, Anaplastic; Enteropathy-Associated T-Cell Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

Metastatic Cancer; Metastatic Melanoma · EGFR

#EGFR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued

49 / 121 pages

← PreviousNext →